Pubblicazioni

• Is the pathology of posterior cortical atrophy clinically predictable?
• Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition
• Apparently isolated CNS involvement in Erdheim-Chester disease: Case report
• Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood
• Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
• Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
• Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis
• Therapeutic Plasmapheresis: A Revision of Literature
• MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis
• Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
• Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
• Disability assessment using Google Maps
• Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy
• Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study
• Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue
• NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab
• Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis
• Correction to: Disability assessment using Google Maps
• Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis
• Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
• Identifying Cladribine prescription pattern in MS: an Italian multicentre study
• Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
• Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study
• COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
• Signs and symptoms of COVID-19 in patients with multiple sclerosis
• A real-world study of alemtuzumab in a cohort of Italian patients
• Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
• Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case-control study
• Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
• SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
• Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience
• Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
• Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis
• Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
• The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis
• Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
• Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
• Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
• Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study
• Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis
• Cladribine vs other drugs in MS: Merging randomized trial with real-life data
• Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
• Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
• The multidimensional assessment of body representation and interoception in multiple sclerosis
• Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
• Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
• Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis
• Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response
• MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
• Switch from fingolimod to ozanimod for safety or intolerance reasons
• Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis
• Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
• Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
• Integrated Cognitive and Neuromotor Rehabilitation in Multiple Sclerosis: A Pragmatic Study
• Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study
• COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
• First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study
• Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study
• The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests
• Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report
• Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease
• Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease
• Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis
• Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study
• Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study
• Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery
• Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity
• CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
• Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease
• Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
• Fingolimod reduces the clinical expression of active demyelinating lesions in MS
• No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study